medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 2

<< Back Next >>

salud publica mex 2016; 58 (2)

Effect of care-delivery delay on the survival of Mexican women with breast cancer

Ángeles-Llerenas A, Torres-Mejía G, Lazcano-Ponce E, Uscanga-Sánchez S, Mainero-Ratchelous F, Hernández-Ávila JE, Morales-Carmona E, Hernández-Ávila M

Language: English
References: 77
Page: 237-250
PDF size: 282.66 Kb.


ABSTRACT

Objective. To estimate the effect of care-delivery delays on survival among women with breast cancer. Materials and methods. A retrospective analysis of 854 women attending 11 hospitals from 2007-2009 was carried out. Kaplan-Meier estimators and a Cox proportional-risk model were employed. Results. A total of 10.5% of cases were diagnosed in stage I. 82% of sampled women delayed care for more than 67 days between noticing a symptom and initiating treatment. The median time from receipt of results of the mammography to biopsy was 31 days (IQR 14-56). Compared with those who were in quartile I (Q1), survival was lower among those in Q3 and Q4 (HR=1.68, 95%CI 0.94-3.00; HR=1.76, 95% CI 1.04-2.98, respectively). Conclusions. To increase survival, it is suggested that the time between receipt of the mammography results and diagnostic biopsy be reduced.


REFERENCES

  1. WHO. Who position paper on mammography screening. Switzerland; 2014.

  2. Ferlay J, Forman D, Mathers CD, Bray F. Breast and cervical cancer in 187 countries between 1980 and 2010. Lancet 2012;379(9824):1390-1391.

  3. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010.

  4. Curado MP, de Souza DL. Cancer burden in Latin America and the Caribbean. Ann Glob Health 2014;80(5):370-377.

  5. Flores-Luna L, Salazar-Martinez E, Duarte-Torres RM, Torres-Mejia G, Alonso-Ruiz P, Lazcano-Ponce E. Prognostic factors related to breast cancer survival. Salud Publica Mex 2008;50(2):119-125.

  6. McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 2012;30(36):4493-4500.

  7. Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health 2014;2:87.

  8. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353(9159):1119-1126.

  9. Smith ER, Adams SA, Das IP, Bottai M, Fulton J, Hebert JR. Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. Cancer Epidemiol Biomarkers Prev 2008;17(10):2882-2890.

  10. Redondo M, Rodrigo I, Pereda T, Funez R, Acebal M, Perea-Milla E, et al. Prognostic implications of emergency admission and delays in patients with breast cancer. Support Care Cancer 2009;17(5):595-599.

  11. Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC cancer 2013;13:240.

  12. Torring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. European journal of cancer 2013;49(9):2187-2198.

  13. Redaniel MT, Martin RM, Ridd MJ, Wade J, Jeffreys M. Diagnostic intervals and its association with breast, prostate, lung and colorectal cancer survival in England: historical cohort study using the Clinical Practice Research Datalink. PloS one 2015;10(5):e0126608.

  14. Farkas DT, Greenbaum A, Singhal V, Cosgrove JM. Effect of insurance status on the stage of breast and colorectal cancers in a safety-net hospital. J Oncol Pract 2012;8(3 Suppl):16s-21s.

  15. Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008;58(1):9-31.

  16. Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY. Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer 2007;110(2):403-411.

  17. Newman LA, Mason J, Cote D, Vin Y, Carolin K, Bouwman D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer 2002;94(11):2844-2854.

  18. Sabik LM, Bradley CJ. Differences in mortality for surgical cancer patients by insurance and hospital safety net status. Med Care Res Rev 2013;70(1):84-97.

  19. Niu X, Roche LM, Pawlish KS, Henry KA. Cancer survival disparities by health insurance status. Cancer Med 2013;2(3):403-411.

  20. Shi R, Taylor H, McLarty J, Liu L, Mills G, Burton G. Effects of payer status on breast cancer survival: a retrospective study. BMC Cancer 2015;15:211.

  21. DeSantis C, Jemal A, Ward E. Disparities in breast cancer prognostic factors by race, insurance status, and education. Cancer Causes Control 2010;21(9):1445-1450.

  22. SSa. Centro Mexicano para la Clasificación de Enfermedades (CEMECE). Guía para el llenado de los Certificados de DEFUNCIÓN Y MUERTE FETAL. Mexico, DF.2007 [accesed 2014 September 20]. available at: www.dgis.salud.gob.mx|www.cemece.salud.gob.mx

  23. Daniel W. Biostatistics: a foundation for analysis in the health sciences. 8th ed. ed. Hoboken, New Jersey: John Wiley Higher and Sons; 2004.

  24. Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H. Patient delay and stage of diagnosis among breast cancer patients in Germany -- a population based study. Br J Cancer 2002;86(7):1034-1040.

  25. Foster RS Jr., Worden JK, Costanza MC, Solomon LJ. Clinical breast examination and breast self-examination. Past and present effect on breast cancer survival. Cancer 1992;69(7 Suppl):1992-1998.

  26. Porta M, Gallen M, Malats N, Planas J. Influence of “diagnostic delay” upon cancer survival: an analysis of five tumour sites. J Epidemiol Community Health 1991;45(3):225-230.

  27. Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet 1999;353(9159):1127-1131.

  28. Sant M, Capocaccia R, Verdecchia A, Esteve J, Gatta G, Micheli A, et al. Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. Int J Cancer 1998;77(5):679-683.

  29. Unger-Saldana K, Miranda A, Zarco-Espinosa G, Mainero-Ratchelous F, Bargallo-Rocha E, Miguel Lazaro-Leon J. Health system delay and its effect on clinical stage of breast cancer: Multicenter study. Cancer 2015;121(13):2198-2206.

  30. Lopez-Carrillo L, Torres-Sanchez L, Lopez-Cervantes M, Rueda-Neria C. Identification of malignant breast lesions in Mexico. Salud Publica Mex 2001;43(3):199-202.

  31. McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer 2015;112 Suppl 1:S108-S115.

  32. Canada PHAo. Organized Breast Cancer Screening Programs in Canada: Report on Program Ottawa, Ontario, Canada,2011.

  33. Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 1999;79(5-6):858-864.

  34. Bright K, Barghash M, Donach M, de la Barrera MG, Schneider RJ, Formenti SC. The role of health system factors in delaying final diagnosis and treatment of breast cancer in Mexico City, Mexico. Breast 2011;20 Suppl 2:S54-S59.

  35. Unger-Saldana K, Pelaez-Ballestas I, Infante-Castaneda C. Development and validation of a questionnaire to assess delay in treatment for breast cancer. BMC Cancer 2012;12:626.

  36. Gullatte MM, Brawley O, Kinney A, Powe B, Mooney K. Religiosity, spirituality, and cancer fatalism beliefs on delay in breast cancer diagnosis in African American women. J Relig Health 2010;49(1):62-72.

  37. Huguley CM Jr., Brown RL, Greenberg RS, Clark WS. Breast self-examination and survival from breast cancer. Cancer 1988;62(7):1389-1396.

  38. Foster RS Jr., Costanza MC. Breast self-examination practices and breast cancer survival. Cancer 1984;53(4):999-1005.

  39. Le Geyte M, Mant D, Vessey MP, Jones L, Yudkin P. Breast self examination and survival from breast cancer. Br J Cancer 1992;66(5):917-918.

  40. Burgess CC, Ramirez AJ, Richards MA, Love SB. Who and what influences delayed presentation in breast cancer? Br J Cancer 1998;77(8):1343-1348.

  41. Auvinen A, Elovainio L, Hakama M. Breast self-examination and survival from breast cancer: a prospective follow-up study. Breast Cancer Res Treat 1996;38(2):161-168.

  42. Pace LE, M punga T, Hategekimana V, Dusengimana JM, Habineza H, Bigirimana JB, et al. Delays in Breast Cancer Presentation and Diagnosis at Two Rural Cancer Referral Centers in Rwanda. Oncologist 2015;20(7):780-788.

  43. Unger-Saldana K, Infante-Castaneda C. Delay of medical care for symptomatic breast cancer: a literature review. Salud Publica Mex 2009;51 Suppl 2:s270-s285.

  44. Pruitt SL, Harzke AJ, Davidson NO, Schootman M. Do diagnostic and treatment delays for colorectal cancer increase risk of death? Cancer Causes Control 2013;24(5):961-977.

  45. Neal RD. Do diagnostic delays in cancer matter? Br J Cancer 2009;101 Suppl 2:S9-S12.

  46. Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguilo A. Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer 2007;43(17):2467-2478.

  47. Terhaar sive Droste JS, Oort FA, van der Hulst RW, Coupe VM, Craanen ME, Meijer GA, et al. Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A populationbased observational study. BMC Cancer 2010;10:332.

  48. Gonzalez-Barcala FJ, Garcia-Prim JM, Alvarez-Dobano JM, Moldes-Rodriguez M, Garcia-Sanz MT, Pose-Reino A, et al. Effect of delays on survival in patients with lung cancer. Clin Transl Oncol 2010;12(12):836-842.

  49. Radzikowska E, Roszkowski-Sliz K, Chabowski M, Glaz P. Influence of delays in diagnosis and treatment on survival in small cell lung cancer patients. Adv Exp Med Biol 2013;788:355-362.

  50. Knaul FM, Arreola-Ornelas H, Velazquez E, Dorantes J, Mendez O, Avila- Burgos L. The health care costs of breast cancer: the case of the Mexican Social Security Institute. Salud Publica Mex 2009;51 Suppl 2:s286-s295.

  51. Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet 1999;353(9159):1132-1135.

  52. Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. Lancet Oncol 2012;13(4):353-365.

  53. Mayo NE, Scott SC, Shen N, Hanley J, Goldberg MS, MacDonald N. Waiting time for breast cancer surgery in Quebec. CMAJ 2001;164(8):1133-1138.

  54. Maclean R, Jeffreys M, Ives A, Jones T, Verne J, Ben-Shlomo Y. Primary care characteristics and stage of cancer at diagnosis using data from the national cancer registration service, quality outcomes framework and general practice information. BMC Cancer 2015;15:500.

  55. Valdivia-Ibarra R, Lombana-Ruiz J, Lazcano-Ponce E, Rojas-Martínez R. Monitoreo de la atención a las mujeres en servicios del sector salud 2012. México: Instituto Nacional de Salud Pública, 2013.

  56. Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol 2010;2010:595167.

  57. Saturno PJ GJ, Armendáriz DM, Candia E, Fernández M, Galván A, Hernández JL, et al. Calidad del primer nivel de atención de los Servicios Estatales de Salud. Propuesta de intervenciones. Cuernavaca: Instituto Nacional de Salud Pública; 2014.

  58. Mohar A, Bargallo E, Ramirez MT, Lara F, Beltran-Ortega A. Available resources for the treatment of breast cancer in Mexico. Salud Publica Mex 2009;51 Suppl 2:s263-s269.

  59. Uscanga-Sanchez S, Torres-Mejia G, Angeles-Llerenas A, Dominguez- Malpica R, Lazcano-Ponce E. Breast cancer screening process indicators in Mexico: a case study. Salud Publica Mex 2014;56(5):528-537.

  60. Perry NM, Party EW. Quality assurance in the diagnosis of breast disease. EUSOMA Working Party. Eur J Cancer 2001;37(2):159-172.

  61. Dregan A, Moller H, Charlton J, Gulliford MC. Are alarm symptoms predictive of cancer survival?: population-based cohort study. Br J Gen Pract 2013;63(617):e807-e812.

  62. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000;321(7261):624-628.

  63. Brandt J, Garne JP, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol 2015;13:33.

  64. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama 2001;285(7):885-892.

  65. Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 2010;28(12):2038-2045.

  66. Barchielli A, Balzi D. Age at diagnosis, extent of disease and breast cancer survival: a population-based study in Florence, Italy. Tumori 2000;86(2):119-123.

  67. Crowe JP Jr., Gordon NH, Shenk RR, Zollinger RM Jr., Brumberg DJ, Shuck JM. Age does not predict breast cancer outcome. Arch Surg 1994;129(5):483-487; discussion 7-8. Artículo original 250 salud pública de méxico / vol. 58, no. 2, marzo-abril de 2016 Ángeles-Llerenas A y col.

  68. Hippisley-Cox J, Coupland C. Symptoms and risk factors to identify women with suspected cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2013;63(606):e11-21.

  69. Rosenberg RD, Haneuse SJ, Geller BM, Buist DS, Miglioretti DL, Brenner RJ, et al. Timeliness of follow-up after abnormal screening mammogram: variability of facilities. Radiology. 2011;261(2):404-413.

  70. Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD, Geller BM, et al. Performance benchmarks for screening mammography. Radiology 2006;241(1):55-66.

  71. Anhang Price R, Zapka J, Edwards H, Taplin SH. Organizational factors and the cancer screening process. J Natl Cancer Inst Monogr 2010;2010(40):38-57.

  72. Reynoso-Noverón N, Mohar A. Cancer in Mexico: recommendations for its control. Salud Publica Mex. 2014 Sep-Oct;56(5):418-20.

  73. Torres-Sánchez LE, Rojas-Martínez R, Escamilla-Núñez C, de la Vara- Salazar E, Lazcano-Ponce E. Cancer mortality trends in Mexico, 1980-2011. Salud Publica Mex 2014;56:473-491.

  74. Bairati I, Jobin E, Fillion L, Larochelle M, Vincent L. Determinants of delay for breast cancer diagnosis. Cancer Detect Prev 2007;31(4):323-331.

  75. Shortell SM. Continuity of medical care: conceptualization and measurement. Medical Care 1976;14(5):377-391.

  76. Wall EM. Continuity of care and family medicine: definition, determinants, and relationship to outcome. J Fam Pract 1981;13(5):655-664.

  77. Donabedian A. The quality of care. How can it be assessed? JAMA 1988;260(12):1743-1748.




2020     |     www.medigraphic.com